Results 21 to 30 of about 2,626 (203)

Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years. [PDF]

Am J Clin Dermatol
Background and Objective There is a need for long-term atopic dermatitis (AD) treatments that can effectively improve AD involvement of the head and neck (H&N) region (referred to as H&N AD).
Chovatiya R, Ribero S, Wollenberg A, Park CO, Silvestre JF, Hong HC, Seneschal J, Saeki H, Thyssen JP, Øland CB, Gjerum L, Maslin D, Blauvelt A.   +12 more
europepmc   +3 more sources

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis

Journal of Dermatological Treatment
Background: Injection site reaction (ISR) is a local phenomenon defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection.Objective: ISR is reported as a frequent adverse event after ...
Fabrizio Martora, Cataldo Patruno, Silvia D’Ascenzo, Maddalena Napolitano   +3 more
doaj   +4 more sources

Tralokinumab in atopic dermatitis [PDF]

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2021
SummaryAtopic dermatitis (AD) is a common chronic inflammatory disease characterized by recurrent eczematous lesions and intense pruritus, and it can have marked negative impact on those affected. Pathophysiologically, AD is complex with genetic predisposition and environmental provocation being important contributors. Mechanistically these can promote
Andreas, Wollenberg, Stephan, Weidinger, Margitta, Worm, Thomas, Bieber   +3 more
openaire   +2 more sources

Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex

JID Innovations, 2023
Tralokinumab, a fully human mAb specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds IL-13 with high affinity, which prevents the interaction of
Maxim A.X. Tollenaere, Christina Mølck, Ian Henderson, Scott Pollack, Philip Addis, Helle Heibroch Petersen, Hanne Norsgaard   +6 more
doaj   +1 more source

Tralokinumab for moderate-to-severe atopic dermatitis: A viable option for dupilumab nonresponders [PDF]

JAAD International
Christine T. Olagun-Samuel, BA, Christine C. Akoh, MD, PhD, Nnaemeka Anyanwu, BS, Elizabeth F. Sher, PhD, Carli D. Needle, BA, Jamie Widawsky, PA-C, MPAS, David E. Cohen, MD, MPH, Emily Milam, MD, Alexandra Flamm, MD, Vikash Oza, MD, Theodora K. Karagounis, MD, MS   +10 more
doaj   +2 more sources

Tralokinumab bei atopischer Dermatitis [PDF]

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2021
ZusammenfassungAtopische Dermatitis (AD) ist eine häufige chronisch‐entzündliche Krankheit mit rezidivierenden ekzematösen Läsionen und starkem Pruritus. Sie kann erhebliche negative Auswirkungen auf die Betroffenen haben. Zur komplexen Pathophysiologie der AD tragen genetische Prädisposition und umweltbedingte Provokationen wesentlich bei ...
Andreas Wollenberg, Stephan Weidinger, Margitta Worm, Thomas Bieber   +3 more
openaire   +1 more source

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

Dermatology and Therapy, 2023
Introduction IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13 ...
Angela J. Okragly, Aya Ryuzoji, Isabella Wulur, Montanea Daniels, Robert D. Van Horn, Chetan N. Patel, Robert J. Benschop   +6 more
doaj   +1 more source

Mechanistic modeling of a human IgG4 monoclonal antibody (tralokinumab) Fab‐arm exchange with endogenous IgG4 in healthy volunteers

CPT: Pharmacometrics & Systems Pharmacology, 2022
Therapeutic IgG4 antibodies engage in Fab‐arm exchange with endogenous human immunoglobulin G4 (IgG4) to form monovalent hybrid molecules. A mechanistic population model was developed to quantitatively characterize the dynamic Fab‐arm exchange of ...
Bing Wang, Jo Goodman, Lorin K. Roskos
doaj   +1 more source

Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]

, 2020
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core   +2 more sources

Selective IL-13 inhibitors for the treatment of atopic dermatitis

Drugs in Context, 2021
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves, Egídio Freitas, Tiago Torres   +2 more
doaj   +1 more source